Is this hysterectomy pathology report appropriate and complete for a total hysterectomy with bilateral salpingo‑oophorectomy performed for International Federation of Gynecology and Obstetrics (FIGO) grade 1 endometrioid adenocarcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathology Report Assessment

This is an excellent and complete hysterectomy pathology report that meets current guideline standards for endometrial carcinoma surgical staging. 1, 2

Key Strengths of This Report

Complete Specimen Documentation

The report appropriately documents all required components for FIGO grade 1 endometrioid adenocarcinoma staging:

  • Total hysterectomy with bilateral salpingo-oophorectomy - the standard surgical procedure for stage I disease 1, 2
  • Sentinel lymph node biopsy - 3 sentinel lymph nodes examined (1 left pelvic, 2 right pelvic), all negative for malignancy, which is the preferred staging approach per current guidelines 1
  • Complete pathologic examination - entire endometrium submitted for histologic review, which is critical given the 15-18% risk of grade upgrading from biopsy to final pathology 3, 4

Appropriate Synoptic Reporting

The report includes a structured synoptic format addressing:

  • Histologic type: No residual tumor identified (complete pathologic response)
  • Myometrial invasion: Not identified
  • Specimen integrity: Intact (avoiding tumor spillage/morcellation as required) 1
  • Lymph node status: 0/3 nodes positive
  • Additional findings: Adenomyosis, atrophic endometrium, benign ovarian and tubal findings

Critical Clinical Context

The comment section appropriately references the original outside biopsy diagnosis and confirms complete examination of the endometrium with no residual disease identified.

Important Clinical Implications

The finding of no residual adenocarcinoma after complete endometrial sampling is not uncommon - this can occur when the diagnostic curettage removes all tumor, particularly in superficial grade 1 lesions. This does not invalidate the original diagnosis or change management.

Risk Stratification Considerations

  • No myometrial invasion identified
  • Negative lymph nodes (0/3)
  • No lymphovascular space invasion mentioned
  • Grade 1 on original biopsy

This patient would be classified as low-risk (FIGO 2023 stage IA1 or IA2) with an estimated 5-year recurrence risk <8% 1

Minor Considerations

The report does not explicitly mention:

  • Lymphovascular space invasion status - should be explicitly stated as present or absent
  • Cervical stromal invasion - stated as "no significant histopathologic changes" but could be more explicit
  • Peritoneal cytology - not mentioned (FIGO/AJCC recommend collection and recording, though not affecting staging) 2

However, these omissions are minor and do not significantly detract from an otherwise comprehensive report. The statement "negative for atypia or malignancy" in the cervix section adequately addresses cervical involvement.

Bottom Line

This pathology report is appropriate, complete, and provides all necessary information for accurate staging, risk stratification, and treatment planning for this patient with FIGO grade 1 endometrioid adenocarcinoma. The surgical approach with sentinel lymph node mapping rather than complete lymphadenectomy aligns with current best practices and reduces surgical morbidity while maintaining staging accuracy 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.